Rac N-Didemethyl Dapoxetine, identified by its CAS number 119357-34-5, is a chemical compound that belongs to the class of selective serotonin reuptake inhibitors (SSRIs). It is primarily researched for its potential use in treating premature ejaculation. The compound is characterized by its dual enantiomeric form, which means it exists as a racemic mixture of two stereoisomers. This structural feature can influence its pharmacological properties, including efficacy and side effects. Rac N-Didemethyl Dapoxetine exhibits a relatively short half-life, which is advantageous for its intended use, allowing for rapid onset and offset of action. The compound is typically administered orally and is known to interact with serotonin receptors, enhancing serotonin levels in the synaptic cleft. Its safety profile and side effects are similar to those of other SSRIs, including potential gastrointestinal disturbances and central nervous system effects. Ongoing research continues to explore its therapeutic potential and optimize its use in clinical settings.

rac N-Didemethyl Dapoxetine

119357-34-5: Rac N-Didemethyl Dapoxetine, identified by its CAS number 119357-34-5, is a chemical compound that belongs to the class of selective serotonin reuptake inhibitors (SSRIs). It is primarily researched for its potential use in treating premature ejaculation. The compound is characterized by its dual enantiomeric form, which means it exists as a racemic mixture of two stereoisomers. This structural feature can influence its pharmacological properties, including efficacy and side effects. Rac N-Didemethyl Dapoxetine exhibits a relatively short half-life, which is advantageous for its intended use, allowing for rapid onset and offset of action. The compound is typically administered orally and is known to interact with serotonin receptors, enhancing serotonin levels in the synaptic cleft. Its safety profile and side effects are similar to those of other SSRIs, including potential gastrointestinal disturbances and central nervous system effects. Ongoing research continues to explore its therapeutic potential and optimize its use in clinical settings.

CAS 119357-34-5

rac N-Didemethyl Dapoxetine

rac-N,N-Didesmethyl Dapoxetine HCl

Ref: 4Z-D-203

Delamanid Impurity 1 Chloride

Ref: 4Z-D-203002

rac N-Didemethyl Dapoxetine

Ref: ST-EA-CP-D9031